132P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC): RATIONALE-307 updated analysis

作者：J. Wang, Shuaiji Lu, X. Yu, Yunfei Hu, J. Zhao, Meiling Sun, Yinan Yu, C. Hu, K. Yang, Yang Song, X. Lin, L. Liang, S. Leaw, W. Zheng · 发表于：Immuno-Oncology Technology · 年份：2022 · DOI：10.1016/j.iotech.2022.100244 · 被引用次数：5 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations、Lung Cancer Research Studies

Interim analysis of the open-label phase 3 RATIONALE-307 study (NCT03594747) demonstrated clinical benefit, including significantly improved progression-free survival (PFS) with a manageable safety profile, of tislelizumab (TIS) plus chemotherapy (chemo) as first-line (1L) therapy in patients (pts) with advanced sq-NSCLC vs chemo alone. Here, we report updated results.